Edition:
United States

People: Syndax Pharmaceuticals Inc (SNDX.OQ)

SNDX.OQ on NASDAQ Stock Exchange Global Select Market

7.68USD
22 Jun 2018
Change (% chg)

$-0.10 (-1.29%)
Prev Close
$7.78
Open
$7.85
Day's High
$7.85
Day's Low
$7.55
Volume
325,581
Avg. Vol
102,148
52-wk High
$15.20
52-wk Low
$7.36

Metzger, Michael 

Mr. Michael A. Metzger is President and Chief Operating Officer of Syndax Pharmaceuticals, Inc. Prior to joining us, Mr. Metzger was President and COO from December 2013 to October 2014 and President and Chief Executive Officer and a member of the board of directors of Regado Biosciences, Inc., a former publicly traded company that merged with Tobira Therapeutics, Inc., from October 2014 to May 2015, where he oversaw the company’s successful merger with Tobira Therapeutics, Inc. in 2015. Previously, Mr. Metzger served as Executive Vice President and Chief Operating Officer at Mersana Therapeutics, Inc., a privately held biopharmaceutical company developing novel immunoconjugate therapies for cancer, from March 2011 to November 2013, and in senior business development positions including leading mergers and acquisitions at Forest Laboratories, LLC, which was acquired by Allergan plc, a publicly traded company, from 2006 to February 2011. Prior to Forest, Mr. Metzger served as Vice President Corporate Development at Onconova Therapeutics, Inc., from 2001 until 2006, and was a Managing Director at MESA Partners, Inc., a venture capital firm, from 1997 to 2001. Mr. Metzger received a B.A. from George Washington University and an M.B.A. in Finance from the New York University Stern School of Business.

Basic Compensation

Total Annual Compensation, USD 346,538
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 2,550,160
Fiscal Year Total, USD 2,896,700

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --